Technology

Gemini Digital Twins are created by combining multi-omic and clinical patient data in specific diseases with Aitia’s patented causal AI and simulation technology, REFS™. These “Digital Twins” link patient characteristics to drug treatments to the “revealed” complex genetic and molecular mechanisms and pathways driving clinical outcomes.

Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across patient cohorts to discover and genetically validate novel drug targets that would otherwise remain hidden for decades. These novel drug targets are then further validated in state-of-the-art preclinical systems and drug candidates across multiple modalities are created.

 Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across patient cohorts for existing drug candidates to better select patient responders versus non-responders and effective combination therapies.